Nadia Rosenthal, Ph.D., FMedSci, FAAHMS
Scientific Director and Professor, The Jackson Laboratory for Mammalian Genetics, the Maxine Groffsky Endowed Chair
Investigates the role of genetic variation and the immune system in tissue repair, focusing on cardiovascular and skeletal muscle disease.
Professor Rosenthal is the Scientific Director of The Jackson Laboratory (Bar Harbor, Maine). She obtained her Ph.D. from Harvard Medical School, where she later directed a biomedical research laboratory, then established and headed the European Molecular Biology Laboratory (EMBL) campus in Rome. She was Founding Director of the Australian Regenerative Medicine Institute at Monash University and founded EMBL Australia as its Scientific Head. Rosenthal is an EMBO member, Fellow of the UK Academy of Medical Sciences and the Australian Academy of Health and Medical Science, is an NH&MRC Australia Fellow, and is the Maxine Groffsky Endowed Chair at The Jackson Laboratory. She also holds a Chair in Cardiovascular Science at Imperial College London.
Professor Rosenthal innovates the use of complex mouse genetic diversity panels to investigate mammalian development, disease, and repair, particularly in cardiovascular and skeletal muscle. Her research has advanced regenerative medicine by elucidating the role of growth factors, stem cells and the immune system in tissue healing after injury. Her book, Heart Development and Regeneration, is considered the definitive text in the field. She has received numerous honorary doctorates and prizes, participates on international advisory boards and committees and is a Founding Editor of Disease Models and Mechanisms, Deputy Editor of Differentiation and Founding Editor-in-Chief of NPJ Regenerative Medicine.
-
Media ReleaseSeptember 27, 2024The Jackson Laboratory celebrates heart education and research with the completion of a new course that empowers cardiology clinicians
Through interactive, case-based lessons, the series empowers cardiology clinicians to move beyond a one-size-fits-all approach, enabling them to adopt more targeted management strategies for their patients. -
ArticleAugust 14, 2024JAX researchers call for genetically diverse models to drive innovation in drug discovery
Diverse mouse models show promise in how we understand and treat diseases, offering a significant improvement over standardized but limited mouse and cellular models. -
Featured ArticleApril 16, 2024Incorporating diverse background genetics to better model human disease
JAX scientists are working to make it more feasible for researchers to incorporate diverse background genetics to better model human disease in mice. -
Research HighlightJuly 26, 2023Genetically diverse mice model the variable human response to SARS-CoV-2
JAX researchers have created a panel of genetically diverse mice that accurately model the highly variable human response to SARS-CoV-2 infection. This will allow scientists to model patient variation in COVID-19 outcome.
-
ArticleAugust 14, 2024From mice to medicine - six questions with Nadia Rosenthal
How working with genetically diverse could revolutionize our understanding of human disease and treatment. -
Research HighlightApril 16, 2024Developing immune therapy without immune toxicity
A team led by David Serreze presents a mouse model for studying severe immune checkpoint inhibition-based damage to heart and skeletal muscle, providing an important resource for maximizing the benefits and minimizing the side effects of vital immunotherapies. -
Press ReleaseDecember 19, 2023JAX's 2023 achievements
JAX is celebrating important research breakthroughs, new faculty and leadership appointments, and crucial advancements in legislation. -
Featured ArticleJuly 10, 2023Rueter and Rosenthal to headline 2023 Forum for Discovery
Harnessing genetics to understand personalized cancer care and regenerative medicine.